Correlation of the Expression of miR-192 in Serum Expression with Left Ventricular Hypertrophy in Patients with Essential Hypertension
-
摘要:
目的 探讨原发性高血压患者血清中miR-192表达与左心室肥厚的相关性。 方法 收集2018年6月至2019年12月期间治疗的187例原发性高血压患者临床资料，行超声心动图检查获得LVPWd、IVST、LVEDD、LVESD、LVEDV、LVESV、LAD、LVEF和LVMI等指标，并根据超声心动图检查结果将患者分为肥厚组和对照组。实时荧光定量PCR检测血清中miR-192表达，ELISA法测定TGF-β1、Ⅰ型前胶原羧基末端肽（PⅠCP）和Ⅲ型前胶原氨基端肽（PⅢNP）水平。 结果 经超声心动图检查，187例原发性高血压患者中，76例出现左心室肥厚（肥厚组），111例未发现左心室肥厚（对照组）；肥厚组患者LVPWT、IVST、LVEDD、LVESD、LVEDV、LVESV、LAD、LVMI和hs-CRP均较对照组升高（P < 0.05）；肥厚组患者血清中miR-192、TGF-β1、PⅢNP和PⅠCP水平较对照组升高（P < 0.05）；Pearson相关分析结果显示，原发性高血压患者血清中miR-192水平与LVPWT、IVST、LVEDD、LVESD、LVEDV、LVESV、LAD、LVMI、TGF-β1、PⅠCP和PⅢNP呈正相关（P < 0.05）；多元线性回归分析结果显示，LVPWT、IVST、LVEDD、LVESV、TGF-β1、PⅠCP和PⅢNP是影响原发性高血压患者血清中miR-192水平的相关因素（P < 0.05）。 结论 血清miR-192水平在原发性高血压左心室肥厚患者中升高，且与左心室肥厚程度及心肌纤维化有关。 Abstract:Objective To investigate the correlation between the expression of miR-192 in serum and left ventricular hypertrophy in patients with essential hypertension. Methods The clinical data of 187 patients with essential hypertension treated from June 2018 to December 2019 were selected. All patients were accepted echocardiography to obtain the indexes of LVPWd, IVST, LVEDD, LVESD, LVEDV, LVESV, LAD, LVEF and LVMI. And according to the results of echocardiography, the patients were divided into the hypertrophic group and control group. The expression of miR-192 in serum was detected by real-time fluorescence quantitative PCR. The levels of TGF-β1, type I procollagen carboxy terminal peptide （PⅠCP） and type III procollagen amino terminal peptide （PⅢNP） were detected by using ELISA. Results According to the results of echocardiography, 76 cases of patients had left ventricular hypertrophy （hypertrophy group）, and 111 cases had no left ventricular hypertrophy （control group）. Compared with the control group, LVPWT, IVST, LVEDD, LVESD, LVEDV, LVESV, LAD, LVMI, and hs-CRP in the hypertrophic group were all increased （P < 0.05）, the serum levels of miR-192, TGF-β1, PⅢNP and PⅠCP in the hypertrophic group were increased （P < 0.05）. Pearson correlation analysis showed that the serum level of miR-192 in patients with essential hypertension was positively correlated with the LVPWT, IVST, LVEDD, LVESD, LVEDV, LVESV, LAD, LVMI, TGF-β1, PⅠCP and PⅢNP （P < 0.05）. The results of multiple linear regression analysis showed that the LVPWT, IVST, LVEDD, LVESV, TGF-β1, PⅠCP, and PⅢNP were related factors that affected serum level of miR-192 in patients with essential hypertension （P < 0.05）. Conclusion The serum level of miR-192 is elevated in patients with essential hypertension and left ventricular hypertrophy, and is related to the degree of left ventricular hypertrophy and myocardial fibrosis. -
Key words:
- miR-192 /
- Left ventricular hypertrophy /
- Myocardial fibrosis /
- Essential hypertension
-
表 1 2组患者一般资料比较（
$\bar x \pm s$ ）Table 1. Comparison on the general data of patients between the two groups （
$\bar x \pm s$ ）指标 肥厚组（n = 76） 对照组（n = 111） t/χ2 P 年龄（岁） 61.11 ± 9.12 58.14 ± 10.16 2.045 0.042* 性别（男/女） 43/33 58/53 0.340 0.560 收缩压（mmHg） 147.24 ± 23.33 142.73 ± 19.71 1.424 0.156 舒张压（mmHg） 84.12 ± 13.35 86.42 ± 11.96 1.235 0.219 高血压病程（a） 11.58 ± 3.45 11.23 ± 3.88 0.623 0.534 高血压家族史[n（%）] 21（27.63） 25（22.52） 0.635 0.426 BMI（kg/m2） 26.56 ± 2.86 27.05 ± 3.15 1.081 0.281 FBG（mmol/L） 5.44 ± 0.61 5.50 ± 0.64 0.708 0.480 TC（mmol/L） 5.34 ± 0.65 5.40 ± 0.67 0.635 0.526 TG（mmol/L） 1.61 ± 0.58 1.68 ± 0.62 0.694 0.488 LDL-C（mmol/L） 3.31 ± 0.74 3.25 ± 0.70 0.595 0.552 HDL-C（mmol/L） 0.96 ± 0.17 0.98 ± 0.18 0.766 0.445 Scr（μmol/L） 72.34 ± 20.72 78.22 ± 20.78 1.901 0.059 BUN（μmol/L） 338.31 ± 87.63 344.26 ± 98.27 0.425 0.671 hs-CRP（mg/L） 4.11 ± 1.60 2.66 ± 1.22 7.033 <0.001* LVPWT（mm） 11.54 ± 0.82 9.16 ± 1.02 16.834 <0.001* IVST（mm） 12.51 ± 1.15 10.66 ± 1.35 9.777 <0.001* LVEDD（mm） 46.41 ± 3.72 42.80 ± 4.01 6.217 <0.001* LVESD（mm） 33.00 ± 3.97 29.54 ± 3.83 5.975 <0.001* LVEDV（mL） 106.50 ± 21.82 96.18 ± 22.18 3.147 0.002* LVESV（mL） 42.98 ± 12.19 35.20 ± 8.76 5.082 <0.001* LAD（mm） 35.88 ± 4.11 32.47 ± 3.88 5.774 <0.001* LVEF（%） 60.07 ± 4.55 61.14 ± 4.61 1.573 0.117 LVMI（g/m2.7） 52.62 ± 5.31 37.02 ± 5.44 19.447 <0.001* *P < 0.05。 
下载: 导出CSV
表 2 2组患者血清中miR-192、TGF-β1、PIIINP和PICP水平比较[（
$ \bar x \pm s $ ），μg/L]Table 2. Comparison on the serum levels of miR-192，TGF-β1，PIIINP and PICP in patients between the two groups [ （
$ \bar x \pm s $ ），μg/L]组别 n miR-192 TGF-β1 PⅠCP PⅢNP 肥厚组 76 1.98 ± 0.13 92.51 ± 9.11 67.93 ± 6.68 61.47 ± 7.46 对照组 111 1.02 ± 0.09 65.35 ± 7.41 50.94 ± 4.82 43.50 ± 6.27 t 60.042 22.414 20.206 4.917 P < 0.001* < 0.001* < 0.001* < 0.001* *P < 0.05。
下载: 导出CSV
表 3 原发性高血压患者血清中miR-192水平与超声心动图和心肌纤维化指标相关性
Table 3. Correlation of the serum level of miR-192 with the indexes of echocardiography and myocardial fibrosis in patients with essential hypertension
指标 相关系数（r） P LVPWT 0.757 < 0.001* IVST 0.572 < 0.001* LVEDD 0.397 < 0.001* LVESD 0.375 < 0.001* LVEDV 0.205 0.005* LVESV 0.366 < 0.001* LAD 0.373 < 0.001* LVEF −0.099 0.176 LVMI 0.778 < 0.001* TGF-β1 0.829 < 0.001* PⅠCP 0.812 < 0.001* PⅢNP 0.715 < 0.001* *P < 0.05。
下载: 导出CSV
表 4 原发性高血压患者血清miR-192水平的多元影响因素分析
Table 4. Analysis on the multivariate influencing factors of the serum level of miR-192 in patients with essential hypertension
指标 标准β系数 标准误差 t P B的95%CI 下限 上限 LVPWT 0.205 0.014 4.592 < 0.001* 0.038 0.095 IVST 0.092 0.011 2.560 0.011* 0.007 0.051 LVEDD 0.070 0.004 2.129 0.035* 0.001 0.015 LVESD 0.017 0.004 0.514 0.608 −0.005 0.009 LVEDV −0.002 0.001 −0.079 0.937 −0.001 0.001 LVESV 0.091 0.001 2.879 0.004* 0.001 0.007 LAD 0.024 0.004 0.729 0.467 −0.005 0.010 LVEF −0.034 0.003 −1.113 0.267 −0.010 0.003 TGF-β1 0.321 0.002 6.339 < 0.001* 0.007 0.013 PⅠCP 0.235 0.002 4.674 < 0.001* 0.007 0.016 PⅢNP 0.143 0.002 3.343 0.001* 0.003 0.011 *P < 0.05。
下载: 导出CSV
-
[1] 韩雅玲. 规范血压健康管理落实健康中国行动[J]. 中华心血管病杂志,2020,48(1):3-4. [2] 韩巍,韩艳丛,邱拥华,等. 高血压合并左心室肥厚患者血清miRNA-29a-3p水平与心肌纤维化的相关性[J]. 河北医科大学学报,2019,40(7):773-776,793. doi: 10.3969/j.issn.1007-3205.2019.07.007 [3] Chau K H,Douglas P S,Pibarot P,et al. Regression of left ventricular mass after transcatheter aortic valve replacement: the PARTNER trials and registries[J]. J Am Coll Cardiol,2020,75(19):2446-2458. doi: 10.1016/j.jacc.2020.03.042 [4] Xiao Y,Liu Y,Liu J,et al. The association between myocardial fibrosis and depressed capillary density in rat model of left ventricular hypertrophy[J]. Cardiovasc Toxicol,2018,18(4):304-311. doi: 10.1007/s12012-017-9438-7 [5] Ezaz G,Trivedi H D,Connelly M A,et al. Differential associations of circulating microRNAs with pathogenic factors in NAFLD[J]. Hepatol Commun,2020,4(5):670-680. doi: 10.1002/hep4.1501 [6] Li Y,Zhang J,Zhang W,et al. MicroRNA-192 regulates hypertrophic scar fibrosis by targeting SIP1[J]. J Mol Histol,2017,48(5-6):357-366. doi: 10.1007/s10735-017-9734-3 [7] 《中国高血压基层管理指南》修订委员会. 中国高血压基层管理指南(2014年修订版)[J]. 中华高血压杂志,2015,23(1):24-43. [8] 姚思宇,刘杰,李瑶,等. 血浆微小RNA-29a与高血压左心室肥厚的关系[J]. 中华心血管病杂志,2019,47(3):215-220. [9] Sibiya M J,Norton G R,Hodson B,et al. Gender-specific contribution of aortic augmentation index to variations in left ventricular mass index in a community sample of African ancestry[J]. Hypertens Res,2014,37(5):1021-1027. [10] 吴春涛,刘苏,李拥军,等. 合并左心室肥厚对高血压患者血清miRNA-455 水平的影响及意义[J]. 山东医药,2019,59(20):5-8. doi: 10.3969/j.issn.1002-266X.2019.20.002 [11] 孙诗敏,姚巍. 血清胱抑素C超敏C反应蛋白红细胞分布宽度与高血压左心室肥厚相关性研究[J]. 中国药物与临床,2018,18(6):927-928. [12] Wang L,Lv Y,Li G,et al. MicroRNAs in heart and circulation during physical exercise[J]. J Sport Health Sci,2018,7(4):433-441. doi: 10.1016/j.jshs.2018.09.008 [13] 苏红燕,张小娟,曹晓青,等. 高血压左心室肥厚患者血清亲环素A和褪黑素的表达水平与意义[J]. 中华心力衰竭和心肌病杂志,2019,3(2):84-88. [14] 吴三五,张友恩,范群雄. 参芪注射液辅助治疗对顽固性心力衰竭患者心功能、心肌纤维化的影响[J]. 海南医学院学报,2018,24(4):456-459. doi: 10.13210/j.cnki.jhmu.20180129.003 [15] Tu J H,Xu Y,Dai Y,et al. Effect of alprostadil on myocardial fibrosis in rats with diabetes mellitus via TGF-β1/Smad signaling pathway[J]. Eur Rev Med Pharmacol Sci,2019,23(21):9633-9641. -
